Needham upgrades Neurocrine Bio to 'Buy'; cites positive physician survey of its drug, 'Crenessity'See details
Neurocrine Biosciences, Inc. - NBIX - stock price prediction, stock price target, analyst ratings from 25 analysts
Neurocrine Biosciences, Inc. has a share price target of US$ 161, revenue growth forecast of 13.5%, and profit growth estimate of 21.3% for FY25, based on top 25 analyst calls.